Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kamea G is a professional-grade topical keratolytic product developed by Tetra Corporation specifically for the treatment of hyperkeratotic skin conditions on the feet. Its active ingredient is glycolic acid, an alpha-hydroxy acid (AHA) that functions as an exfoliant to debride significant scale buildup and callusing. By reducing the cohesion of corneocytes in the stratum corneum, it promotes the shedding of thickened skin. Kamea G is typically dispensed through medical offices and is often used as part of a comprehensive foot care regimen alongside urea-based moisturizers like Kamea 20 to manage chronic hyperkeratosis and improve skin texture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kamea G.